Scott+Scott, Attorneys at Law, LLP Alerts Investors to the Filing of Securities Class Action Against Obalon Therapeutics, Inc.

NEW YORK--()--Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, is notifying investors that a class action lawsuit has been filed against Obalon Therapeutics, Inc. (NASDAQ:OBLN) (“Obalon” or the “Company”) and other defendants, related to alleged violations of federal securities laws. If you purchased Obalon securities between October 5, 2016 and January 23, 2018, you are encouraged to contact a Scott+Scott attorney at (844) 818-6980 for additional information.

Obalon Therapeutics, Inc. manufactures medical devices, including a medical gastric balloon for weight loss therapy.

The lawsuit alleges that the defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, defendants failed to disclose: (1) that the Company recognized revenue in violation of Generally Accepted Accounting principles; (2) that the Company lacked adequate internal controls over accounting and financial reporting; and (3) that, as a result of the foregoing, the Company’s financial statements and defendants’ statements about Obalon’s business, operations, and prospects, were materially false and misleading at all relevant times.

On January 23, 2018, Obalon issued a press release disclosing that “a purported whistleblower contacted KPMG LLP, the Company’s independent auditors, to make certain allegations relating to allegedly improper revenue recognition during the Company’s fourth fiscal quarter of 2017.” The Company further stated that “Obalon’s Audit Committee will oversee an internal investigation of these allegations.”

On this news, Obalon’s stock price fell $1.73 per share, or 33.3%, to close at $3.46 per share on January 23, 2018. The $3.46 closing price represented a total decline of nearly 77%, from the Initial Public Offering price of $15.00 per share.

What You Can Do

If you purchased Obalon securities between October 5, 2016 and January 23, 2018, inclusive, or if you have questions about this notice or your legal rights, please contact attorney Rhiana Swartz at (844) 818-6980, or at Investors have until April 16, 2018, to move for lead plaintiff.

About Scott+Scott, Attorneys at Law, LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.

Attorney Advertising


Scott+Scott, Attorneys at Law, LLP
Rhiana Swartz, 844-818-6980

Release Summary

Securities Class Action Filed Against Obalon Therapeutics - Interested Investors Encouraged to Contact Scott+Scott




Scott+Scott, Attorneys at Law, LLP
Rhiana Swartz, 844-818-6980